Tucatinib’s mechanism of action

Tucatinib (Tucatinib) is an oral, small-molecule tyrosine kinase inhibitor that specifically targets HER2 (human epidermal growth factor receptor 2)-positive breast cancer. HER2 is a transmembrane receptor tyrosine kinase that is overexpressed in some cancer cells, including breast cancer. This overexpression leads to abnormal proliferation and survival of cancer cells, becoming one of the key factors in tumor growth and progression.

Tucatinib prevents the activation of the HER2 signaling pathway by highly selectively inhibiting the tyrosine kinase activity of the HER2 receptor. This mechanism is mainly reflected in the following aspects:

1.BlockHER2activation:HER2 receptors are overexpressed on the surface of cancer cells, often through dimerization (binding with another HER2receptor) or with otherHER family of receptors (such as HER1, HER3, HER4) form heterodimers to activate their tyrosine kinase activity. Tucatinib blocks this activation process by binding to the tyrosine kinase domain of HER2 , thereby inhibiting the conduction of downstream signaling pathways.

2.Inhibit cell proliferation and survival signaling pathways: HER2 will activate multiple intracellular signaling pathways after activation, including PI3K/AKT and MAPK pathways. These pathways play key roles in cell proliferation, survival, and migration. Tucatinib (Tucatinib) By inhibiting the activation of these signaling pathways, it reduces the proliferation and survival ability of cancer cells, thereby inhibiting tumor growth.

3.Enhance the effect of combination therapy: Tucatinib (Tucatinib) Usually combined with other anti- HER2Drugs used in combination, such as trastuzumab and capecitabine. Trastuzumab is a monoclonal antibody that labels cancer cells and encourages the immune system to attack them by binding to the HER2 receptor. Capecitabine is a chemotherapy drug that interferes with DNA synthesis in cancer cells, causing cell death. Tucatinib (Tucatinib) By being used in combination with these drugs, it provides multiple mechanisms of anti-tumor effects and significantly improves the therapeutic effect.

4.Penetrating the blood-brain barrier: HER2 A considerable number of patients with positive breast cancer will develop brain metastases, making treatment difficult. Tucatinib (Tucatinib) can penetrate the blood-brain barrier and inhibit HER2 positive cancer cells in the brain, providing a new treatment option for patients with brain metastases.

In general, tucatinib blocks key signaling pathways for cancer cell proliferation and survival by highly selectively inhibiting the tyrosine kinase activity of HER2 receptors. It has shown significant clinical efficacy especially in combination therapy and provides an important treatment for HER2 positive breast cancer patients.